JOSEPH WEIGEL: Open Payments
NPI 1063563542 · CULVER CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,604 in 170 payments from 10 companies in 2025. Trend: 2023 $3,615 · 2024 $3,895 · 2025 $4,604
Food & beverage: $4,383Education: $221
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 25 | $789 |
| Otsuka America Pharmaceutical, Inc. | 31 | $728 |
| Alkermes, Inc. | 23 | $624 |
| Teva Pharmaceuticals USA, Inc. | 24 | $623 |
| Vanda Pharmaceuticals Inc. | 17 | $595 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $497 |
| Neurocrine BioSciences, Inc. | 17 | $338 |
| Janssen Pharmaceuticals, Inc | 14 | $306 |
| ABBVIE INC. | 4 | $86 |
| Lundbeck LLC | 1 | $18 |
Products named: COBENFY, HETLIOZ, ARISTADA, CAPLYTA, REXULTI, UZEDY, INGREZZA, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
